Abstract

Improved vaccines against influenza would enhance our ability to decrease the deleterious effects of epidemics. This study aims to develop genetic vaccination strategies against influenza. DNA and adenoviral vaccines have been developed against different strains of influenza, including recently identified pandemic H1N1, H5N1 avian flu and seasonal flu. In addition, studies are ongoing to identify and optimize conserved regions of influenza in order to develop a vaccine that provides more universal protection. Testing has been conducted to evaluate candidates, as well as adjuvants to boost immune response, and determine the optimal strategies for immunization. Several candidates showed promising results and testing is continuing, using DNA and DNA prime with inactivated vaccine boost or nanoparticles displaying HA antigens.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005003-12
Application #
8745604
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2013
Total Cost
$1,695,001
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Erbelding, Emily J; Post, Diane J; Stemmy, Erik J et al. (2018) A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis 218:347-354
Yassine, Hadi M; McTamney, Patrick M; Boyington, Jeffery C et al. (2018) Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera. Sci Rep 8:8628
Andrews, Sarah F; Graham, Barney S; Mascola, John R et al. (2018) Is It Possible to Develop a ""Universal"" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem. Cold Spring Harb Perspect Biol 10:
DeZure, Adam D; Coates, Emily E; Hu, Zonghui et al. (2017) An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines 2:15
Andrews, Sarah F; Joyce, M Gordon; Chambers, Michael J et al. (2017) Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci Immunol 2:
Wheatley, Adam K; Whittle, James R R; Lingwood, Daniel et al. (2015) H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. J Immunol 195:602-10
Yassine, Hadi M; Boyington, Jeffrey C; McTamney, Patrick M et al. (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med :
Whittle, James R R; Wheatley, Adam K; Wu, Lan et al. (2014) Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol 88:4047-57
Kanekiyo, Masaru; Wei, Chih-Jen; Yassine, Hadi M et al. (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102-6
Wei, Chih-Jen; Yassine, Hadi M; McTamney, Patrick M et al. (2012) Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med 4:147ra114

Showing the most recent 10 out of 17 publications